ESTEVE completed the acquisition of the HRA Pharma Rare Diseases business of Perrigo for €275m.

ESTEVE, an international specialty pharmaceutical company, completed the acquisition of the HRA Pharma Rare Diseases business of Perrigo, a pharmaceutical and consumer goods company, for €275m. "This transaction aims to advance on the path of covering the unmet patients' needs, in line with ESTEVE's purpose of improving people's lives, and is another step towards the company's vision of being an international and specialist pharma company," Staffan Schüberg, ESTEVE CEO.